BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
BioCentury This Week
Latest Episodes
Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route...
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Note: This episode was briefly published with an incorrect audio file, which has since been corrected.FDA is prepared to approve psychedelic therapies for chronic psychiatric disor...
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss of antisense oligonucleotide therapy ...
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCent...
Ep. 384 - Back to School Special: The global FIH trials race
China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world have gotten the message and know that this is no time for complac...
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
